Roche’s Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS
pharmafile | October 11, 2018 | News story | Research and Development | Ocrevus, Roche, multiple sclerosis, pharma
Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in the treatment of relapsing and primary progressive forms of multiple sclerosis (MS), showing a wide range of benefits over other therapies at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) in Berlin.
In relapsing MS, the findings demonstrated that patients who had received continuous treatment with Ocrevus saw better outcomes brain atrophy and confirmed disability progression (CDP) compared to those who switched therapies after the first two years of interferon beta-1α treatment.
Those who began treatment two years earlier saw lower loss of whole brain, white matter and cortical grey matter tissue after five years, and saw “significant and sustained reductions” in 24-week confirmed disability progression, at 16.1% versus 21.3% for those switching from interferon beta-1α.
Overall, those RMS patients who received earlier treatment saw their disease activity reduced earlier, with less disability progression.
In primary progressive MS patients, those treated three to five years earlier experienced less disability progression, with a 9.6% reduction in those who were continuously treated compared to those who switched from placebo. Upper limb disability progression saw reductions of 13.4%.
“From the moment of diagnosis, reducing disease progression is an important goal for people with MS,” remarked Dr Stephen Hauser, Chair of the Scientific Steering Committee of the OPERA studies, Professor of Neurology at the University of California, San Francisco, and Director of the UCSF Weill Institute for Neurosciences. “The new data presented at ECTRIMS demonstrate that Ocrevus’ efficacy continued over five years in relapsing and primary progressive MS, and notably, include the largest body of evidence for any medicine to significantly slow disability progression in primary progressive MS.”
Matt Fellows
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
